Popular terms

Follow us on Twitter
twitter icon@FreshPatents

Web & Computing
Cloud Computing
Ecommerce
Search patents
Smartphone patents
Social Media patents
Video patents
Website patents
Web Server
Android patents
Copyright patents
Database patents
Programming patents
Wearable Computing
Webcam patents

Web Companies
Apple patents
Google patents
Adobe patents
Ebay patents
Oracle patents
Yahoo patents

[SEARCH]

Receptor patents



      

This page is updated frequently with new Receptor-related patent applications.




Date/App# patent app List of recent Receptor-related patents
05/12/16
20160131989 
 Optical writing device and image forming device patent thumbnailOptical writing device and image forming device
An optical writing device performing optical writing onto a photoreceptor, including: a light-emitting unit including a plurality of light-emitting elements that form a plurality of element rows spaced from one another in a sub scanning direction, each of the light-emitting elements having a main scanning direction position differing from a main scanning direction position of any other one of the light-emitting elements; a plurality of signal output units, one for each element row, each outputting a light amount signal for each light-emitting element in a corresponding element row, each light amount signal indicating an amount of light to be emitted by a corresponding light-emitting element; and a plurality of drive units, one for each light-emitting element, each, when receiving a light amount signal for a corresponding light-emitting element, supplying a drive current in accordance with the light amount signal to the corresponding light-emitting element.. .
Konica Minolta, Inc.


05/12/16
20160131665 
 Srm/mrm assay for the insulin receptor protein patent thumbnailSrm/mrm assay for the insulin receptor protein
Specific peptides, and derived ionization characteristics of the peptides, from the insulin receptor protein (ir), and its isoforms ir-a and ir-b, that are particularly advantageous for quantifying the ir protein, ir-a isoform and/or ir-b isoform, directly in biological samples that have been fixed in formalin by the method of selected reaction monitoring (srm) mass spectrometry, or what can also be termed as multiple reaction monitoring (mrm) mass spectrometry. Such biological samples are chemically preserved and fixed and are selected from tissues and cells treated with formaldehyde containing agents/fixatives including formalin-fixed tissue/cells, formalin-fixed/paraffin embedded (ffpe) tissue/cells, ffpe tissue blocks and cells from those blocks, and tissue culture cells that have been formalin fixed and or paraffin embedded.
Expression Pathology, Inc.


05/12/16
20160131638 
 Immunity to folate receptors patent thumbnailImmunity to folate receptors
This document provides methods and materials related to assessing immunity to folate receptors. For example, methods and materials for assessing frα immunity in a mammal are provided.
Mayo Foundation For Medical Education And Research


05/12/16
20160131110 
 Conduit assembly for a lightning protection cable of a wind turbine rotor blade patent thumbnailConduit assembly for a lightning protection cable of a wind turbine rotor blade
The present disclosure is directed to a system and method for reducing electrical arcs caused by lightning strikes in a rotor blade of a wind turbine. The rotor blade includes a lightning protection system with at least one lightning receptor connected to at least one conductor and a conduit assembly.
General Electric Company


05/12/16
20160130569 
 A laglidadg homing endonuclease cleaving the t cell receptor alpha gene and uses thereof patent thumbnailA laglidadg homing endonuclease cleaving the t cell receptor alpha gene and uses thereof
Disclosed herein are compositions for inactivating the human tcr-alpha gene comprising engineered laglidadg homing endonucleases (lhes) and their derivatives, particularly derived from members of the \-onul subfamily of lhes. Polynucleotides encoding such endonucleases, vectors comprising said polynucleotides, cells comprising or having been treated with such endonucleases, and therapeutic compositions deriving therefore are also provided..
Pregenen Inc.


05/12/16
20160130563 
 Compositions and methods for enhancing virus replication patent thumbnailCompositions and methods for enhancing virus replication
Described herein is a method of enhancing virus replication in permissive cells that express a receptor to fgf2 protein. The method includes administering fgf2 protein or a functional variant thereof and the virus to the permissive cells.
Ottawa Hospital Research Institute


05/12/16
20160130365 
 Methods and compositions for prognosis, diagnosis, and treatment of adam8-expressing cancer patent thumbnailMethods and compositions for prognosis, diagnosis, and treatment of adam8-expressing cancer
The transmembrane metalloproteinase-disintegrin adam8 mediates cell adhesion and shedding of ligands, receptors, and extracellular matrix components. Adam8 is abundantly expressed in breast tumors and derived metastases compared to normal tissue, especially in triple-negative breast cancers (tnbcs).
Tufts University


05/12/16
20160130363 
 Agonistic antibodies to trkc receptors and uses thereof patent thumbnailAgonistic antibodies to trkc receptors and uses thereof
There are provided herein novel monoclonal antibodies that selectively bind and/or activate trkc receptors, pharmaceutical compositions thereof and the use thereof for treating or preventing conditions which require activation of trkc, such as amyotrophic lateral sclerosis and other neurodegenerative conditions and motor neuron diseases. The monoclonal antibodies are useful to screen for agents that share the same binding epitope on the trkc receptor..
The Royal Institution For The Advancement Of Learning/mcgill University


05/12/16
20160130357 
 Compositions comprising chimeric antigen receptors, t cells comprising the same, and methods of using the same patent thumbnailCompositions comprising chimeric antigen receptors, t cells comprising the same, and methods of using the same
Provided are isolated nucleic acid molecules encoding chimeric antigen receptors (cars) that bind to tumor antigens. Also provided are isolated polypeptides and cars encoded by the isolated nucleic acid molecules, vectors that include the isolated nucleic acid molecules, cells that include the isolated nucleic acid molecules, methods of making the same, and methods for using the same to generate a persisting population of genetically engineered t cells in a subject, expanding a population of genetically engineered t cells in a subject, modulating the amount of cytokine secreted by a t cell, reducing the amount of activation-induced calcium influx into a t cell, providing an anti-tumor immunity to a subject, treating a mammal having a muc1-associated disease or disorder, stimulating a t cell-mediated immune response to a target cell population or tissue in a subject, and imaging a muc1-associated tumor..
The University Of North Carolina At Charlotte


05/12/16
20160130354 
 Antibodies to the b12-transcobalamin receptor patent thumbnailAntibodies to the b12-transcobalamin receptor
The present invention provides anti-tcblr antibodies and related compositions, which may be used in any of a variety of therapeutic methods for the treatment of cancer, tumors and other proliferative diseases and disorders.. .
The Research Foundation Of State University Of New York


05/12/16
20160130352 

Rhamm, a co-receptor and its interactions with other receptors in cancer cell motility and the identification of cancer prognitor cell populations


Cd44 is an integral hyaluronan receptor that can either promote or inhibit motogenic signaling in tumor cells. Rhamm is a non-integral cell surface (cd168) and intracellular hyaluronan binding protein that promotes cell motility in vitro and whose expression is strongly upregulated in aggressive tumors.
The Regents Of The University Of California


05/12/16
20160130345 

Combination of vaccination and inhibition of the pd-1 pathway


The present invention relates to a vaccine/inhibitor combination comprising an rna vaccine comprising at least one rna comprising at least one open reading frame (orf) coding for at least one antigen and a composition comprising at least one pd-1 pathway inhibitor, preferably directed against pd-1 receptor or its ligands pd-l1 and pd-l2. The present invention furthermore relates to a pharmaceutical composition and a kit of parts comprising the components of such a vaccine/inhibitor combination.
Curevac Ag


05/12/16
20160130342 

Novel p2x7 epitopes


The invention relates to purinergic (p2x) receptors, to generation of antibodies and to use of antibodies and immunogens for detection and treatment of a disease or condition, especially cancer.. .
Biosceptre International Limited


05/12/16
20160130334 

Notch inhibition in the treatment and prevention of obesity


The present invention is directed to methods of treating or preventing obesity by administering agents that inhibit the notch signaling pathway. Antibodies that inhibit the binding of delta like 4 ligand (dll4) to notch receptors may be used for this purpose..
The Brigham And Women's Hospital, Inc.


05/12/16
20160130330 

Mammalian receptors as targets for antibody and active vaccination therapy against mold infections


The present invention provides therapeutic compositions and methods for treating and preventing fungal disease or conditions including mucormycosis. The therapeutic methods and compositions of the invention include antibody, antibody fragments, sirna and vaccine compositions having or directed against a grp78 polypeptide or an antigenic fragment of the polypeptide..
Los Angeles Biomedical Research Institute At Harbor-ucla Medical Center


05/12/16
20160130322 

A growth hormone secretagogue receptor based protein, nucleic acids and methods and uses thereof


Ghrelin is a peptide hormone that binds its receptor, growth hormone secretatgogue receptor 1a (ghs-r1 a, ghrelin receptor), to promote adiposity and obesity in mammals. Ghrelin and its receptor are targets for therapeutic intervention to treat obesity-related disease and cancer.

05/12/16
20160130320 

Modified chimeric polypeptides with improved pharmacokinetic properties


The present invention provides vegf antagonists with improved pharmacokinetic properties. According to certain embodiments, a fusion polypeptide capable of antagonizing vegf activity is provided comprising a modified extracellular ligand binding domain of a vegf receptor fused to a multimerizing component..
Regeneron Pharmaceuticals, Inc.


05/12/16
20160130319 

High-stability t-cell receptor and preparation method and application thereof


The present invention provides a high-stability t cell receptor. The t cell receptor has mutations in its hydrophobic core domain causing the enhancement of stability thereof.
Guangzhou Xiangxue Pharmaceutical Co. Ltd


05/12/16
20160130315 

Tumor tissue-penetrating peptide specific to neuropilin and fusion protein having same peptide fused therein


A tumor tissue-penetrating peptide specifically binding to neuropilin, or a fusion protein, a small molecule drug, a nanoparticle, or a liposome having the peptide fused therein is provided, as well as a method for preparing the same and a pharmaceutical composition comprising the same for treating, diagnosing, or preventing cancer or angiogenesis-related diseases. The tumor tissue-penetrating peptide is fused to the c-terminus of an anticancer antibody heavy-chain constant region (fc) and the fused antibody specifically binds to neuropilin, and specifically accumulates in tumor tissue, widens intercellular gaps between tumor vascular endothelial cells, promotes extravasation, increases infiltration within tumor tissue, and shows a remarkably increased in vivo tumor-suppressing activity.
Ajou University Industry-academic Cooperation Foundation


05/12/16
20160130282 

Mercaptoamidine derivatives and methods of use


Are useful in treating conditions or disorders prevented by or ameliorated by histamine-3 receptor ligands. Also disclosed are pharmaceutical compositions of compounds of formula (i), methods for using such compounds and compositions, and a process for preparing the compounds..

05/12/16
20160130273 

Process for making cgrp receptor antagonists


The invention encompasses a novel process for making piperidinone carboxamide indane and azainane derivatives, which are cgrp receptor antagonists useful for the treatment of migraine.. .
Merck Sharp & Dohme Corp.


05/12/16
20160130270 

Fluorinated 3-(2-oxo-3-(3-arylpropyl)imidazolidin-1-yl)-3-arylpropanoic acid derivatives


The invention relates to fluorinated compounds and their use as integrin receptor antagonists. Novel fluorinated 3-(2-oxo-3-(3-arylpropyl)imidazolidin-1-yl)-3-arylpropanoic acid derivatives and pharmaceutically acceptable salts or solvates thereof and their use are described..
Scifluor Life Sciences, Inc.


05/12/16
20160130262 

N-substituted azetidine derivatives


The present invention relates to novel n-substituted azetidine derivatives<of the formula (i); wherein sermf is a selective estrogen receptor modilator fragment; x is no atom, o, s, ch2, carbonyl, n—r5; r1 is h, (c1-8)alkyl, (c3-8)cycloalkyl, (c3-6)heterocycloalkyl, (c2-6)alkenyl, (c2-6)alkynyl, (c1-4)alkylcarbonyl, (c1-4)alkoxy(c2-4)alkyl, (c3-6)cycloalkyl(c1-3)-alkyl, (c3-6)heterocycloalkyl(c1-3)alkyl, each independently optionally substituted with one or more halogen, nitrile, hydroxyl or (c1-2)alkyl; r5 is h, (c1-3)alkyl, optionally substituted with one or more fluorine; r17, r18 and r19 are independently of each other h, fluorine, nitrile or (c1-3)-alkyl, optionally substituted with one or more fluorine; or a prodrug, isotopically-labelled derivative or pharmaceutically acceptable salt thereof, >to pharmaceutical compositions comprising these compounds and to their use in therapy, in particular to their use for the prevention or treatment of ovulatory dysfunction, uterine cancer, endometrium cancer, ovarian cancer, endometriosis, osteoporosis, prostate cancer, benign prostatic hypertrophy, and breast cancer, in particular er-positive breast cancer, more in particular er-positive, hormone treatment-resistant breast cancer. Said n-substituted azetidine derivatives have estrogen receptor alpha (erα) antagonistic and—in certain embodiments—selective estrogen receptor downregulating (serd) activity in er-positive breast cancer cells..

05/12/16
20160130255 

Ethynyl derivatives


The present invention relates to ethynyl derivatives as metabotropic glutamate receptor antagonists (negative allosteric modulators) for use in the treatment of, e.g., anxiety and pain, depression, fragile-x syndrome, autism spectrum disorders, parkinson's disease, and gastroesophageal reflux disease (gerd).. .
Hoffmann-la Roche Inc.


05/12/16
20160130254 

Novel cyp17 inhibitors/antiandrogens


Wherein r1 to r8, a, b, z1, and z2 are as defined in the claims and pharmaceutically acceptable salts and esters thereof are disclosed. The compounds of formula (i) possess utility as androgen receptor antagonists (inhibitors) and/or cytochrome p450 monooxygenase 17α-hydroxylase/17,20-lyase (cyp17) inhibitors.

05/12/16
20160130232 

4-alkynyl imidazole derivative and medicine comprising same as active ingredient


There are provided 4-alkynylimidazole derivatives represented by the following general formula (i) or phamaceutically acceptable salts thereof; the derivatives have a superior ep4 receptor antagonistic action and are useful as pharmaceuticals for the treatment of diseases associated with the ep4 receptor, for example, as anti-inflammatory and/or analgesic drugs for inflammatory diseases and diseases that involve various kinds of pains, and further as pharmaceuticals for the treatment of immune diseases that result from inflammations as evoked by tissue destruction due to the activation of th1 cells and/or th17 cells:. .
Kaken Pharmaceutical Co., Ltd.


05/12/16
20160130226 

Spiro-substituted oxindole derivatives having ampk activity


The present invention relates to compounds of formula (i), which have valuable pharmacological properties, in particular are activators of ampk and which are therefore useful in the treatment of certain disorders that can be prevented or treated by activation of this receptor. The compounds are suitable for treatment and prevention of diseases which can be influenced by this receptor, such as metabolic diseases, in particular diabetes type 2..
Boehringer Ingelheim International Gmbh


05/12/16
20160129109 

Universal anti-tag chimeric antigen receptor-expressing t cells and methods of treating cancer


The present invention provides a universal, yet adaptable, anti-tag chimeric antigen receptor (at-car) system which provides t cells with the ability and specificity to recognize and kill target cells, such as tumor cells, that have been marked by tagged antibodies. As an example, αfitc-car-expressing t cells have been developed that specifically recognize various human cancer cells when those cells are bound by cancer-reactive fitc-labeled antibodies.
University Of Maryland, Baltimore


05/12/16
20160129108 

Therapeutic combinations comprising anti-cd73 antibodies and uses thereof


The present invention provides therapeutic combinations featuring anti-cd73 antibodies (e.g., medi9447) and a2a receptor inhibitors and methods of using such combinations for reducing tumor-mediated immunosuppression.. .
Medimmune Limited


05/12/16
20160129094 

T cell receptors directed against bob1 and uses thereof


The technology relates in part to compositions and methods for inducing an immune response against a bob1 antigen. Provided are methods for treating hyperproliferative diseases by inducing an immune response against a bob1 antigen; the immune response may be induced using a bob1 polypeptide fragment, or by specifically targeting bob1-expressing cells using t cell receptors directed against bob1..
Leiden University Medical Center


05/12/16
20160129089 

Combination therapy


The present disclosure relates to a method for treatment or prevention of diseases have an increased level of insulin-like growth factor i (igf-i). The method comprises administration of a somatostatin analogs having agonistic activity in combination with an oligonucleotide targeted to growth hormone receptor (ghr) to a subject in need..
Antisense Therapeutics Ltd


05/12/16
20160129036 

Adenosine analogs and their use


The invention provides adenosine analog compounds that act at p2y receptors, e.g., the p2y2 receptor, including pharmaceutical compositions; and uses thereof to treat or prevent diseases associated with that receptor, e.g., disorders relating to mucus secretion, such as cystic fibrosis, chronic obstructive pulmonary disorder (copd), asthma, constipation, chronic idiopathic constipation, dry mouth (xerostomia), gum disease, and gastrointestinal problems caused by radiation and chemotherapy for cancer.. .
Microdose Therapeutx, Inc.


05/12/16
20160129032 

Receptor-type kinase modulators and methods of use


The present invention provides compounds for modulating receptor kinase activity, particularly ephrin and egfr, and methods of treating diseases mediated by receptor kinase activity utilizing the compounds and pharmaceutical compositions thereof. Diseases mediated by receptor kinase activity include, but are not limited to, diseases characterized in part by abnormal levels of cell proliferation (i.e.
Symphony Evolution, Inc.


05/12/16
20160129023 

Bicyclic aryl sphingosine 1-phosphate analogs


Compounds that have agonist activity at one or more of the s1p receptors are provided. The compounds are sphin-gosine analogs that, after phosphorylation, can behave as agonists at s1p receptors..
Biogen Ma Inc.


05/12/16
20160129014 

Fulvestrant formulations


The invention provides a fulvestrant composition comprising a pharmaceutically acceptable alcohol, polysorbate 80, an antioxidant, and castor oil, which is substantially or completely free of a non-aqueous ester solvent and which demonstrates excellent storage stability. The composition may be used to treat hormone receptor positive metastatic breast cancer in a subject..
Fresenius Kabi Usa, Llc


05/12/16
20160129012 

Compositions and methods for treating allergic inflammation through inhibition of ntrk1


The invention provides methods of treating allergic inflammatory conditions using an anti-neurotrophin tyrosine kinase receptor 1 (ntrk1)-based therapeutic agent, and related compositions and methods.. .
Children's Hospital Medical Center


05/12/16
20160129010 

Substituted benzoazepines as toll-like receptor modulators


Provided are compositions and methods useful for modulation of signaling through the toll-like receptors tlr7 and/or tlr8. The compositions and methods have use in treating or preventing disease, including cancer, autoimmune disease, infectious disease, inflammatory disorder, graft rejection, and graft-versus-host disease..
Array Biopharma, Inc.


05/12/16
20160129000 

Method of treatment for mental disorders


The invention relates to a medicament or a method for treating mental disorders, in detail, adhd comprising lurasidone, or a combination of lurasidone and a d4 receptor agonist.. .
Sumitomo Dainippon Pharma Co., Ltd.


05/12/16
20160128996 

Bicyclic aza compounds as muscarinic m1 receptor agonists


This invention relates to compounds (formula (1)) that are agonists of the muscarinic m1 receptor and which are useful in the treatment of muscarinic m1 receptor mediated diseases. Also provided are pharmaceutical compositions containing the compounds and the therapeutic uses of the compounds.
Heptares Therapeutics Limited


05/12/16
20160128980 

Methods of treating ckd using predictors of fluid retention


The disclosure relates to methods of treating chronic kidney disease and diabetic nephropathy using predictors of fluid retention to minimize the risk of adverse events. The methods disclosed are particularly useful in treatments involving endothelin receptor antagonists, and more particularly, atrasentan and pharmaceutically acceptable salts thereof..
Abbvie Inc.


05/12/16
20160128969 

Solid forms of selective androgen receptor modulators


The present invention relates to solid forms of (s)—n-(4-cyano-3-(trifluoromethyl)phenyl)-3-(4-cyanophenoxy)-2-hydroxy-2-methylpropanamide and process for producing the same.. .
Gtx, Inc.


05/12/16
20160128968 

Method of treating androgen receptor (ar) -positive breast cancers with selective androgen receptor modulator (sarms)


This invention relates to the treatment of breast cancer in a subject, for example a female subject. Including methods of: treating metastatic breast cancer; refractory breast cancer; ar-positive breast cancer; ar-positive refractory breast cancer; ar-positive metastatic breast cancer; ar-positive and er-positive breast cancer; triple negative breast cancer; advanced breast cancer; breast cancer that has failed serm (tamoxifen, toremifene), aromatase inhibitor, trastuzumab (herceptin, ado-trastuzumab emtansine), pertuzumab (perjeta), lapatinib, exemestane (aromasin), bevacizumab (avastin), and/or fulvestrant treatments; metastasis in a subject suffering from breast cancer; comprising administering to the subject a therapeutically effective amount of a selective androgen receptor modulator (sarm) compound..
Gtx, Inc.


05/12/16
20160128902 

Chair with backrest having pressure points for stimulating mechanoreceptors


A chair having a backrest with pressure points arranged in rows corresponding to vertebra in the cervical, thoracic and lumbar sections of the spine. The rows within the cervical and thoracic sections have at least four pressure points spaced laterally.
Jcc&p, Llc


05/05/16
20160126999 

Communication antenna unit and mobile terminal apparatus


A mobile terminal apparatus includes a casing in which a circuit board, a battery pack, and a power receptor are provided. A power feeder is provided in the battery pack and is connected to the power receptor.
Panasonic Intellectual Property Management Co., Ltd.


05/05/16
20160124327 

Electrophotographic photoreceptor, electrophotographic photoreceptor cartridge, image forming apparatus, and polyarylate resin


An electrophotographic photoreceptor comprises a conductive support and, at least a photosensitive layer on the conductive support, wherein the photosensitive layer includes a polyarylate resin and the polyarylate resin has a repeating structure represented by formula (1), and the amount of bisphenol residues represented by formula (3) after the polyarylate resin is hydrolyzed, is 0.2% to 1%, in terms of intensity ratio, based on the total amount of bisphenol residues represented by formula (2) and formula (3) after the polyarylate resin is hydrolyzed, the bisphenol residues being detected with a gas chromatograph employing a hydrogen flame ionization detector (fid).. .
Mitsubishi Chemical Corporation


05/05/16
20160123996 

Methods and compositions for diagnosis and prognosis of renal injury and renal failure


The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular, the invention relates to using assays that detect one or more markers selected from the group consisting of prostatic acid phosphatase, lactotransferrin, soluble erythropoietin receptor, von willebrand factor, soluble endothelial protein c receptor, and beta-2-glycoprotein 1 as diagnostic and prognostic biomarkers in renal injuries..
Astute Medical, Inc.


05/05/16
20160123962 

Il-34 receptor assays and uses thereof


Methods are disclosed for identifying activators and inhibitors of actions of interleukin-34 (il-34) that are independent of the colony stimulating factor-1 (csf-1) receptor (csf-1r) and play a role in development, homeostasis and disease.. .
Albert Einstein College Of Medicine, Inc.


05/05/16
20160123956 

Modified membrane spanning proteins and methods for the preparation and use thereof


In accordance with the present invention, there are provided functionally modulated tool receptors which are useful for drug discovery and development. In certain aspects and embodiments as described herein, a sophisticated and powerful approach has been designed that allows the rapid development of enhanced receptors, while simultaneously exploring millions of possibilities for improved properties with respect to such properties as protein expression, homogeneity, stabilization, conformational and activation pathway selectivity, antigenicity, immunogenicity, and the like.
Abilita Bio, Inc.


05/05/16
20160123919 

Opioid detection based on high quality graphene transistor arrays and a synthetic mu receptor


The present invention provides methods for fabricating field-effect devices and sensor arrays. The field of the invention also pertains to methods of using the sensors individually, in combination, and in array fashion to detect molecules.
The Trustees Of The University Of Pennsylvania


05/05/16
20160123325 

Compressor and autonomously inspecting oil


Systems and techniques are disclosed to sense a temperature and a flow rate of oil in a compressor. A compressor includes: a casing; a frame on the casing; a fixed scroll on the frame; an orbiting scroll supported by the frame and defining a compression chamber while engaging the fixed scroll; and a crank shaft.
Lg Electronics Inc.


05/05/16
20160122984 

Lavatory drain


An adjustable lavatory drain assembly includes a receptor and a cover. The receptor includes a lower end and an upper end.
Kohler Co.


05/05/16
20160122832 

G-protein coupled receptor (gpcr)-based biosensors and uses thereof


Provided herein are gpcr-based chemical biosensors that can have a sensing unit, a processing unit, and a response unit that can be used to detect a chemical of interest. Also provided herein are methods of making and using the gpcr-based chemical biosensors..
Georgia Tech Research Corporation


05/05/16
20160122779 

Plants having increased resistance to pathogens and producing said plants


The invention relates to a plant having increased resistance to pathogens, wherein the protein sobir1 from arabidopsis thaliana or a homologous protein, which is capable of interacting with at least one of the prr receptor proteins rlp30 or rlp1, and at least one of the prr receptor proteins rlp30 or rlp1 are overexpressed in comparison with the wild-type plant or are newly synthesized. The pathogens are preferably fungi, in particular from the genus sclerotinia, and bacteria, in particular from the genus xanthomonas.
Eberhard Karls UniversitÄt TÜbingen


05/05/16
20160122766 

Methods and compositions for reducing immunosupression by tumor cells


The present disclosure provides, in part, methods of discovering immunotherapy targets in vivo, therapeutic compositions (e.g., shrna, immunoresponsive cells expressing shrna and/or a chimeric antigen receptors (car)), and methods of use thereof.. .
The General Hospital Corporation D/b/a Massachusetts General Hospital


05/05/16
20160122436 

Single chain binding molecules comprising n-terminal abp


The present invention relates to a single chain binding molecule comprising at least three binding domains, wherein the first binding domain is capable of binding to serum albumin and is positioned at the n-terminus of the second binding domain, said second binding domain is capable of binding to a cell surface molecule on a target cell and the third binding domain is capable of binding to the t cell cd3 receptor complex. Moreover, the invention relates to methods for the production of such binding molecule, a nucleic acid sequence encoding it, a vector comprising said nucleic acid sequence and a host cell expressing the binding molecule of the invention.
Amgen Research (munich) Gmbh


05/05/16
20160122433 

Anti-pdgfr-beta antibodies and uses thereof


The present invention provides antibodies that bind to platelet derived growth factor receptor beta (pdgfr-beta) and methods of using the same. According to certain embodiments of the invention, the antibodies are fully human antibodies that bind to human pdgfr-beta with high affinity.
Regeneron Pharmaceuticals, Inc.


05/05/16
20160122411 

Cartilage-binding fusion proteins


Provided herein are fusion proteins comprising a first domain that specifically binds to the extracellular domain of a growth factor receptor, and a second domain that specifically binds to a cartilage matrix component, and pharmaceutical composition comprising these fusion proteins. Methods of treating musculoskeletal diseases using the fusion proteins and pharmaceutical composition disclosed herein are also provided..
Merrimack Pharmaceuticals, Inc.


05/05/16
20160122406 

Analogs of pituitary adenylate cyclase-activating polypeptide (pacap) and methods for their use


This invention relates to analogs of pituitary adenylate cyclase-activating polypeptide (pacap), which are agonists for the pacap/vasoactive intestinal peptide (vip) receptors: pac1, vpac1 and vpac2 receptors. These pacap analogs can be used as prophylactic/therapeutic agents for a wide range of medical disorders.
The Administrators Of The Tulane Educational Fund


05/05/16
20160122394 

Fc receptor (fcrn) binding peptides and uses thereof


The invention provided herein includes isolated polypeptides that specifically block the interaction between neonatal fc receptor (fcrn) and albumin. Blocking the interaction treats diseases and conditions caused by increased amounts of albumin or modified albumin that possesses pathogenic properties wherein it is deemed desirable to decrease albumin levels.
The Brigham And Women's Hospital, Inc.


05/05/16
20160122389 

Peptides with antagonistic activities against natural cxcr4


A peptide effective in blocking the cxc-chemokine receptor 4 (cxcr4) mediated hiv-1 nl4-3 (x4-tropic) infection with an ic50 value of less than 50 μm.. .
Pharis Biotech Gmbh


05/05/16
20160122388 

Conotoxin peptides, pharmaceutical compositions and uses thereof


The present disclosure describes analog conotoxin peptides of the α-contoxin peptide rgia. These analog conotoxin peptides block the α9α10 subtype of the nicotinic acetylcholine receptor (nachr) and can be used for treating pain, inflammatory conditions, inflammation, and/or cancer..
University Of Utah Research Foundation


05/05/16
20160122386 

V1a receptor agonists


Compounds of formula (i), salts thereof, and compositions and uses thereof are described. The compounds are useful as v1a vasopressin agonists, for the treatment of, e.g., complications of cirrhosis, including bacterial peritonitis, hrs2 and refractory ascites..
Ferring B.v.


05/05/16
20160122359 

Spiro-lactam nmda receptor modulators and uses thereof


Disclosed are compounds having enhanced potency in the modulation of nmd a receptor activity. Such compounds are contemplated for use in the treatment of conditions such as depression and related disorders.
Naurex, Inc.


05/05/16
20160122319 

Cyclic aminomethyl pyrimidine derivative


The present invention provides a cyclic aminomethyl pyrimidine derivative and a pharmaceutically acceptable salt thereof with high selectivity for dopamine d4 receptors, which are useful for treating a disease such as attention deficit hyperactivity disorder. Specifically, a compound of formula (1) or a pharmaceutically acceptable salt thereof is provided, wherein n and m are independently 1 or 2; ra is c1-6 alkyl group, c3-6 cycloalkyl group, or amino group; rb is hydrogen atom, c1-6 alkyl group or the like, provided that when ra is amino group, then rb is hydrogen atom; rc1 and rc2 are independently hydrogen atom, or c1-6 alkyl group; rd1 and rd2 are independently hydrogen atom, fluorine atom or the like; ring q is an optionally-substituted pyridyl group or an optionally-substituted isoquinolyl group; and the bond having a dashed line is a single or double bond..
Sumitomo Dainippon Pharma Co., Ltd.


05/05/16
20160122317 

1-sulfonyl piperidine derivatives as modulators of prokineticin receptors


The present invention provides compounds of formula (i) and pharmaceutically acceptable salts thereof in which m, n, w, x, y, z, r1, r2, r3, r4 and r5 are as defined in the specification, compositions containing them and their use in therapy.. .
Takeda Pharmaceutical Company Limited


05/05/16
20160122305 

Topical compositions and methods of use thereof


The invention is generally directed to compositions useful for improving the aesthetic appearance of human skin and the use of those compounds for improving the appearance of human skin, including improving skin tone, reducing the appearance of dark circles under the eyes, and reducing inflammation in the skin. The compositions typically comprise adrenergic receptor agonists..
Avon Products, Inc.


05/05/16
20160122300 

Acetylcholinesterase inhibitor compounds and 5ht4 serotonergic receptor agonists, with promnsia effect, methods for the preparation thereof and pharmaceutical compositions containing the same


As well as their enantiomers and their racemics, their acid salts, their hydrates or their solvation products. Among a large number of possible meanings, x represents a halogen, y an oxygen atom; all of the coefficients m, n, r and s have the value 1, r represents an ethyl and r′ a cycloalkyl.





Follow us on Twitter
twitter icon@FreshPatents

###

This listing is a sample listing of patent applications related to Receptor for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Receptor with additional patents listed. Browse our RSS directory or Search for other possible listings.


0.413

4651

2 - 1 - 104